Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2020 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MIRUM PHARMACEUTICALS INC | 10 | Q2 2024 | 13.6% |
ARCUTIS BIOTHERAPEUTICS INC | 10 | Q2 2024 | 17.0% |
KRYSTAL BIOTECH INC | 10 | Q2 2024 | 8.5% |
PHATHOM PHARMACEUTICALS INC | 10 | Q2 2024 | 8.6% |
VAXCYTE INC | 10 | Q2 2024 | 4.8% |
TARSUS PHARMACEUTICALS INC | 10 | Q2 2024 | 2.7% |
KALVISTA PHARMACEUTICALS INC | 10 | Q2 2024 | 2.4% |
ANAPTYSBIO INC | 10 | Q2 2024 | 2.5% |
COGENT BIOSCIENCES INC | 10 | Q2 2024 | 2.4% |
MERUS N V | 10 | Q2 2024 | 1.4% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-08-15 |
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR/A | 2023-02-07 |
13F-HR | 2023-02-03 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-10 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.